Litigation Details for Rigshospitalet v. Shire-NPS Pharmaceuticals, Inc. (D. Mass. 2021)
✉ Email this page to a colleague
Rigshospitalet v. Shire-NPS Pharmaceuticals, Inc. (D. Mass. 2021)
| Docket | ⤷ Start Trial | Date Filed | 2021-09-29 |
| Court | District Court, D. Massachusetts | Date Terminated | 2022-05-10 |
| Cause | 35:271 Patent Infringement | Assigned To | Allison Dale Burroughs |
| Jury Demand | Plaintiff | Referred To | |
| Patents | 7,056,886; 7,847,061; 9,060,992; 9,539,310; 9,545,434; 9,545,435; 9,555,079; 9,572,867; 9,592,273; 9,592,274; 9,968,655; 9,968,656; 9,968,658; 9,974,835; 9,974,837; 9,981,014; 9,981,016; 9,987,334; 9,987,335; 9,993,528 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Rigshospitalet v. Shire-NPS Pharmaceuticals, Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Start Trial .
Details for Rigshospitalet v. Shire-NPS Pharmaceuticals, Inc. (D. Mass. 2021)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2021-09-29 | External link to document | |||
| 2021-09-29 | 1 | Complaint | until the patent on the active ingredient (U.S. Patent No. 7,056,886) expires. That patent is set to …GLP-2 SBS Patent that issued was U.S. Patent No. 7,847,061 (the “’061 Patent”). The ’061 Patent issued …draft) to the Patent Office as a provisional patent application or otherwise seek patent protection of…Applications and Patents with the Patent Office; holding itself out as owning the GLP-2 SBS Patents by listing… USA, identifies the ’061 Patent as “a patent for which a claim of patent infringement could reasonably | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
